United Therapeutics Corporation (UTHR)

Receivables turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue (ttm)	US$ in thousands	2,877,400	2,756,200	2,616,700	2,498,300	2,327,500	2,204,300	2,110,900	1,981,300	1,936,300	1,860,000	1,788,700	1,768,300	1,685,500	1,655,200	1,590,600	1,506,100	1,483,300	1,409,500	1,430,900	1,442,500
Receivables	US$ in thousands	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Receivables turnover		—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

December 31, 2024 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $2,877,400K ÷ $—K
= —

The receivables turnover ratio for United Therapeutics Corporation is not available for the periods listed, as indicated by the symbol "—". The receivables turnover ratio measures how efficiently a company is able to collect payments on its credit sales during a specific period. A higher receivables turnover ratio typically indicates that the company is effectively managing its accounts receivable and converting them into cash quickly.

Without the specific values for the receivables turnover ratio, it is difficult to provide a detailed analysis of United Therapeutics Corporation's performance in this area. The company may not publicly disclose this information or the data might not be available at this time.

Regardless, a thorough evaluation of the receivables turnover ratio would require comparing the company's turnover ratio to industry benchmarks, historical performance, and analyzing any trends over time to assess the effectiveness of the company's credit and collection policies.